| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Can community pharmacists treat hepatitis C virus?
|
Wade, Amanda J
|
|
|
5 |
9 |
p. 790-791
|
artikel
|
| 2 |
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial
|
Radley, Andrew
|
|
|
5 |
9 |
p. 809-818
|
artikel
|
| 3 |
Drug-induced liver injury in older people
|
Lucena, M Isabel
|
|
|
5 |
9 |
p. 862-874
|
artikel
|
| 4 |
Eliminating viral hepatitis in the COVID-19 era: weighing challenge and opportunity
|
The Lancet Gastroenterology & Hepatology,
|
|
|
5 |
9 |
p. 789
|
artikel
|
| 5 |
Gastrointestinal and liver involvement in patients with COVID-19
|
Xu, Yongxing
|
|
|
5 |
9 |
p. 798-799
|
artikel
|
| 6 |
Gastrointestinal and liver involvement in patients with COVID-19
|
Barrera, Francisco J
|
|
|
5 |
9 |
p. 799
|
artikel
|
| 7 |
Gastrointestinal and liver involvement in patients with COVID-19 – Authors' reply
|
Qiu, Yun
|
|
|
5 |
9 |
p. 799-800
|
artikel
|
| 8 |
Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)
|
Wei, Lai
|
|
|
5 |
9 |
p. 839-849
|
artikel
|
| 9 |
Gluten: dietary villain or innocent bystander?
|
Biesiekierski, Jessica R
|
|
|
5 |
9 |
p. 808
|
artikel
|
| 10 |
Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?
|
Raine, Tim
|
|
|
5 |
9 |
p. 794-796
|
artikel
|
| 11 |
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
|
Loomba, Rohit
|
|
|
5 |
9 |
p. 829-838
|
artikel
|
| 12 |
Ozanimod in Crohn's disease: a promising new player
|
Sleutjes, Jasmijn A M
|
|
|
5 |
9 |
p. 791-792
|
artikel
|
| 13 |
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
|
Feagan, Brian G
|
|
|
5 |
9 |
p. 819-828
|
artikel
|
| 14 |
Paraprobiotics for irritable bowel syndrome: all that glitters is not gold
|
Enck, Paul
|
|
|
5 |
9 |
p. 797
|
artikel
|
| 15 |
Paraprobiotics for irritable bowel syndrome: all that glitters is not gold – Authors' reply
|
Andresen, Viola
|
|
|
5 |
9 |
p. 797-798
|
artikel
|
| 16 |
Practice patterns of diagnostic upper gastrointestinal endoscopy during the initial COVID-19 outbreak in England
|
Markar, Sheraz R
|
|
|
5 |
9 |
p. 804-805
|
artikel
|
| 17 |
Preoperative oral antibiotics in colon surgery
|
Meyer, Jeremy
|
|
|
5 |
9 |
p. 801
|
artikel
|
| 18 |
Preoperative oral antibiotics in colon surgery
|
Lambregts, Merel M C
|
|
|
5 |
9 |
p. 800-801
|
artikel
|
| 19 |
Preoperative oral antibiotics in colon surgery
|
Koskenvuo, Laura
|
|
|
5 |
9 |
p. 801-802
|
artikel
|
| 20 |
Preoperative oral antibiotics in colon surgery – Authors' reply
|
Basany, Eloy Espin
|
|
|
5 |
9 |
p. 802-803
|
artikel
|
| 21 |
Reduced rate of hospital admissions for liver-related morbidities during the initial COVID-19 outbreak
|
Eshraghian, Ahad
|
|
|
5 |
9 |
p. 803-804
|
artikel
|
| 22 |
Research in brief
|
Baker, Holly
|
|
|
5 |
9 |
p. 807
|
artikel
|
| 23 |
Small molecule oral targeted therapies in ulcerative colitis
|
Shivaji, Uday N
|
|
|
5 |
9 |
p. 850-861
|
artikel
|
| 24 |
The impact of COVID-19 on hepatitis elimination
|
Wingrove, Chris
|
|
|
5 |
9 |
p. 792-794
|
artikel
|
| 25 |
Use of Cytosponge as a triaging tool to upper gastrointestinal endoscopy during the COVID-19 pandemic
|
di Pietro, Massimiliano
|
|
|
5 |
9 |
p. 805-806
|
artikel
|
Tijdschrift beschrijving